https://www.selleckchem.com/pr....oducts/Nimodipine(Ni
Eighteen percent knew the benefit of LCS, and 69% were not aware of any screening harms. CONCLUSIONS LCS-eligible nonparticipants are more likely to be female, active smokers, have fewer total pack-years of smoking, chronic kidney disease, a history of prior malignancy, and not have chronic obstructive pulmonary disease, coronary artery disease, or liver disease. Targeted education about the benefits and harms of LCS, verification of insurance coverage, and providing convenient screening locations may improve participation.
Like
Comment
Share
